Effects of Acetate-Free Citrate-Containing Dialysate on Metabolic Acidosis, Anemia, and Malnutrition in Hemodialysis Patients

Artificial Organs

Volumn 36, Issue 3, 2012, Pages 282-290

  Kuragano, Takahiro ^a   Kida, Aritoshi ^a   Furuta, Minoru ^a   Yahiro, Mana ^a   Kitamura, Rie ^a   Otaki, Yoshinaga ^a   Nonoguchi, Hiroshi ^a   Matsumoto, Akihide ^b   Nakanishi, Takeshi ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

^b Seishoukai Aoi Hospital   (Japan)

Author keywords

Acetate free citrate dialysate; Anemia; Malnutrition; Metabolic acidosis

Indexed keywords

HEMODIALYZERS; METABOLISM; NUTRITION; PATIENT TREATMENT;

ACETATE-FREE CITRATE DIALYZATE; ALKALINE BUFFER; ANEMIA; CLINICAL EFFECTS; DIALYSATES; ERYTHROPOIESIS-STIMULATING AGENTS; HAEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN LEVELS; METABOLIC ACIDOSIS;

DIALYSIS;

ACETIC ACID; ANTIANEMIC AGENT; BICARBONATE; CALCIUM; CELLULOSE TRIACETATE; CHLORIDE; CITRIC ACID; CREATININE; GLUCOSE; HEMOGLOBIN; MAGNESIUM; POLY(METHYL METHACRYLATE); POLYETHERSULFONE; POLYSULFONE; POTASSIUM; SERUM ALBUMIN; SODIUM;

ACID BASE BALANCE; ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; BICARBONATE BLOOD LEVEL; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIALYSATE; DIALYSIS MEMBRANE; FEMALE; FLOW RATE; HEALTH STATUS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MALNUTRITION; METABOLIC ACIDOSIS; NUTRITIONAL STATUS; PRIORITY JOURNAL; TREATMENT DURATION; ULTRAFILTRATION;

EID: 84857973972     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2011.01349.x     Document Type: Article

References (25)

1. Grassmann A, Uhlenbusch-Körwer I, Bonnie-Schorn E, Vienken J. Composition and management of hemodialysis fluids. In: Vienken J, ed. Good Dialysis Practice, Vol. 2. Lengerich Berlin: Pabst Science Publishers, 2000, pp. 13-25.
2. Amore A, Cirina P, Mitola S, etal. Acetate intolerance is mediated by enhanced synthesis of nitric oxide by endothelial cells. J Am Soc Nephrol 1997;8:1431-6.
3. Grandi E, Govoni M, Furini S, etal. Induction of NO synthase 2 in ventricular cardiomyocytes incubated with a conventional bicarbonate dialysis bath. Nephrol Dial Transplant 2008;23:2192-7.
4. Guarnieri GF, Carretta R, Toigo G, Campanacci L. Acetate intolerance in chronic uremic patients. Nephron 1979;24:212-6.
5. Todeschini M, Macconi D, Fernández NG, etal. Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. Am J Kidney Dis 2002;40:783-93.
6. Kossmann RJ, Gonzales A, Callan R, Ahmad S. Increased efficiency of hemodialysis with citrate dialysate: a prospective controlled study. Clin J Am Soc Nephrol 2009;4:1459-64.
7. Ahmad S, Callan R, Cole J, Blagg C. Increased dialyzer reuse with citrate dialysate. Hemodial Int 2005;9:264-7.
8. Mehrotra R, Kopple JD, Wolfson M. Metabolic acidosis in maintenance dialysis patients: clinical considerations. Kidney Int Suppl 2003;64:S13-25.
9. Bazilinski NG, Dunea G, Ing TS. Treatment of metabolic alkalosis in renal failure. Int J Artif Organs 1987;10:284-6.
10. Bommer J, Locatelli F, Satayathum S, etal. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004;44:661-71.
11. Kuragano T, Furuta M, Kida A, etal. Case of a maintenance hemodialysis patient in whom a change of sensitivity to acetate was suspected. ASAIO J 2010;56:488-90.
12. Qureshi AR, Alvestrand A, Divino-Filho JC, etal. Inflammation, malnutrition, and cardiac disease as predictors of mortality in hemodialysis patients. J Am Soc Nephrol 2002;13:S28-36.
13. Bergström J. Anorexia in dialysis patients. Semin Nephrol 1996;16:222-9.
14. Bergström J. Metabolic acidosis and nutrition in dialysis patients. Blood Purif 1995;13:361-7.
15. Tazza L, Di Napoli A, Bossola M, etal. Lazio dialysis registry: ageing of patients on chronic dialysis: effects on mortality-a 12-year study. Nephrol Dial Transplant 2009;24:940-7.
16. Tsubakihara Y, Nishi S, Akiba T, etal. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial 2010;14:240-75.
17. Kilpatrick RD, Critchlow W, Fishbane S, etal. Greater Epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:1077-83.
18. Solomon SD, Uno H, Lewis EF, etal. Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-55.
19. Gaweda AE, Goldsmith LJ, Brier ME, Aronoff GR. Iron, inflammation, dialysis adequacy, nutritional status, and hyperparathyroidism modify erythropoietic response. Clin J Am Soc Nephrol 2010;5:576-81.
20. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB. Can acidosis and hyperphosphataemia result in increased erythropoietin dosing in haemodialysis patients? Nephrology 2006;11:394-9.
21. Yenu JY, Kaysen GA. Factors influencing serum albumin in dialysis patients. Am J Kidney Dis 1998;32(Suppl. 4):S118-25.
22. Agarwal R, Davis JL, Smith L. Serum albumin is strongly associated with erythropoietin sensitivity in hemodialysis patients. Clin J Am Soc Nephrol 2008;3:98-104.
23. Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Suppl 2005;20:S21-7.
24. Barreto DV, Barreto FC, Liabeuf S, etal. Plasma interleukin-6 is independently associated with mortality in both hemodialysis and pre-dialysis patients with chronic kidney disease. Kidney Int 2010;77:550-6.
25. Shoji T, Tsubakihara Y, Fujii M, Imai E. Hemodialysis associated hypotension as an independent risk factor for two-year mortality in hemodialysis patients. Kidney Int 2004;66:1212-20.